Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH; American Society of Clinical Oncology.

J Clin Oncol. 2011 Nov 1;29(31):4189-98. doi: 10.1200/JCO.2010.34.4614. Epub 2011 Sep 26. Review. Erratum in: J Clin Oncol. 2014 Jun 1;32(19):2117. Dosage error in article text.

2.

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM.

J Clin Oncol. 2006 Jun 20;24(18):2932-47. Epub 2006 May 22. Erratum in: J Clin Oncol. 2006 Nov 20;24(33):5341-2.

PMID:
16717289
3.

Antiemetic Use in Oncology: Updated Guideline Recommendations from ASCO.

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Somerfield MR, Lyman GH.

Am Soc Clin Oncol Educ Book. 2012:532-40. doi: 10.14694/EdBook_AM.2012.32.532.

4.

Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Celio L, Agustoni F, Testa I, Dotti K, de Braud F.

Tumori. 2012 May-Jun;98(3):279-86. doi: 10.1700/1125.12393. Review.

5.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28.

PMID:
21711119
6.

Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.

Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.

Cancer Med. 2015 Mar;4(3):333-41. doi: 10.1002/cam4.373. Epub 2014 Dec 23.

7.

Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.

Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M.

Support Care Cancer. 2016 Mar;24(3):1405-11. doi: 10.1007/s00520-015-2905-4. Epub 2015 Sep 8.

8.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH.

J Clin Oncol. 2017 Oct 1;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789. Epub 2017 Jul 31. Review.

PMID:
28759346
9.

Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.

Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111/j.1445-5994.2011.02637.x.

PMID:
22141732
10.

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.

Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Saito M, Morrow G, Hesketh P.

Support Care Cancer. 2011 Mar;19 Suppl 1:S25-32. doi: 10.1007/s00520-010-0976-9. Epub 2010 Aug 28.

PMID:
20803039
11.

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.

Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.

Support Care Cancer. 2013 May;21(5):1453-60. doi: 10.1007/s00520-012-1691-5. Epub 2013 Jan 26.

12.

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.

Fabi A, Malaguti P.

Expert Opin Pharmacother. 2013 Apr;14(5):629-41. doi: 10.1517/14656566.2013.771166. Epub 2013 Feb 18. Review.

PMID:
23414148
13.

Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.

Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV, Pizer B.

Cochrane Database Syst Rev. 2016 Feb 2;2:CD007786. doi: 10.1002/14651858.CD007786.pub3. Review.

PMID:
26836199
14.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
16.

[Medical treatment of chemotherapy-induced nausea and vomiting].

Herrstedt J.

Ugeskr Laeger. 2007 Feb 26;169(9):799-805. Review. Danish.

PMID:
17355844
17.
18.

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.

Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P; MASCC/ESMO.

Support Care Cancer. 2011 Mar;19 Suppl 1:S37-42. doi: 10.1007/s00520-010-0994-7. Epub 2010 Sep 9.

PMID:
20824481
19.

Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.

Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K.

Int J Clin Oncol. 2016 Feb;21(1):1-12. doi: 10.1007/s10147-015-0852-1. Epub 2015 Jun 17.

20.

Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.

Kaushal J, Gupta MC, Kaushal V, Bhutani G, Dhankar R, Atri R, Verma S.

Singapore Med J. 2010 Nov;51(11):871-5.

Supplemental Content

Support Center